Cargando…

The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman

Objectives: International cardiovascular guidelines recommend prescribing a combination of five evidence-based medications (EBM) for acute coronary syndrome (ACS) patients post-revascularization. This study aims to assess the prevalence and impact of prescribing the full (five medications) versus pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Hadithy, Dalia Ahmed, Al-Maqbali, Juhaina Salim, Al-Riyami, Adil, Al Za’abi, Mohammed, Al-Zakwani, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204429/
https://www.ncbi.nlm.nih.gov/pubmed/37218961
http://dx.doi.org/10.3390/pharmacy11030079
_version_ 1785045831752089600
author Al-Hadithy, Dalia Ahmed
Al-Maqbali, Juhaina Salim
Al-Riyami, Adil
Al Za’abi, Mohammed
Al-Zakwani, Ibrahim
author_facet Al-Hadithy, Dalia Ahmed
Al-Maqbali, Juhaina Salim
Al-Riyami, Adil
Al Za’abi, Mohammed
Al-Zakwani, Ibrahim
author_sort Al-Hadithy, Dalia Ahmed
collection PubMed
description Objectives: International cardiovascular guidelines recommend prescribing a combination of five evidence-based medications (EBM) for acute coronary syndrome (ACS) patients post-revascularization. This study aims to assess the prevalence and impact of prescribing the full (five medications) versus partial (four medications or fewer) EBM combination on major adverse cardiovascular and cerebrovascular events (MACCE) in patients with ACS post-revascularization. Methods: Data from patients with ACS who had revascularization between January 2016 and September 2021 were collected retrospectively. Patients were then followed up until March 2022 for MACCE. Results: The full EBM combination was prescribed to 70% of the patients. However, after taking into account the presence of contraindications and clinical factors, the actual adherence to the guidelines was 95%. Patients who received the full EBM combination were younger (58 versus 62 years; p = 0.0 and 3) and had lower rates of chronic kidney disease (11% versus 41%; p < 0.001) and heart failure (9% versus 20%; p = 0.012) when compared to patients who received the partial EBM. Compared to the partial EBM group, the full EBM group was associated with lower MACCE rates (54% versus 37%, p = 0.012). After employing the propensity score technique utilizing the 1:1 nearest neighbor matching method without replacement, the univariate findings were further re-affirmed with those on full EBMs (compared to those on partial EBMs) associated with a significant reduction in the MACCE rate (average treatment effect of −25%; 95% confidence interval: −10–−40%; p = 0.001). Conclusions: The full EBM utilization was significantly high in our setting and in line with international guidelines. The full EBM combination was predominantly prescribed in younger and less comorbid patients and was associated with lower MACCE rates. The findings were further reaffirmed by the propensity score matching method.
format Online
Article
Text
id pubmed-10204429
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102044292023-05-24 The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman Al-Hadithy, Dalia Ahmed Al-Maqbali, Juhaina Salim Al-Riyami, Adil Al Za’abi, Mohammed Al-Zakwani, Ibrahim Pharmacy (Basel) Article Objectives: International cardiovascular guidelines recommend prescribing a combination of five evidence-based medications (EBM) for acute coronary syndrome (ACS) patients post-revascularization. This study aims to assess the prevalence and impact of prescribing the full (five medications) versus partial (four medications or fewer) EBM combination on major adverse cardiovascular and cerebrovascular events (MACCE) in patients with ACS post-revascularization. Methods: Data from patients with ACS who had revascularization between January 2016 and September 2021 were collected retrospectively. Patients were then followed up until March 2022 for MACCE. Results: The full EBM combination was prescribed to 70% of the patients. However, after taking into account the presence of contraindications and clinical factors, the actual adherence to the guidelines was 95%. Patients who received the full EBM combination were younger (58 versus 62 years; p = 0.0 and 3) and had lower rates of chronic kidney disease (11% versus 41%; p < 0.001) and heart failure (9% versus 20%; p = 0.012) when compared to patients who received the partial EBM. Compared to the partial EBM group, the full EBM group was associated with lower MACCE rates (54% versus 37%, p = 0.012). After employing the propensity score technique utilizing the 1:1 nearest neighbor matching method without replacement, the univariate findings were further re-affirmed with those on full EBMs (compared to those on partial EBMs) associated with a significant reduction in the MACCE rate (average treatment effect of −25%; 95% confidence interval: −10–−40%; p = 0.001). Conclusions: The full EBM utilization was significantly high in our setting and in line with international guidelines. The full EBM combination was predominantly prescribed in younger and less comorbid patients and was associated with lower MACCE rates. The findings were further reaffirmed by the propensity score matching method. MDPI 2023-04-26 /pmc/articles/PMC10204429/ /pubmed/37218961 http://dx.doi.org/10.3390/pharmacy11030079 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Al-Hadithy, Dalia Ahmed
Al-Maqbali, Juhaina Salim
Al-Riyami, Adil
Al Za’abi, Mohammed
Al-Zakwani, Ibrahim
The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman
title The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman
title_full The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman
title_fullStr The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman
title_full_unstemmed The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman
title_short The Prevalence and Impact of Evidence-Based Medications on Cardiovascular and Cerebrovascular Outcomes in Patients with Acute Coronary Syndrome Post-Revascularization in Oman
title_sort prevalence and impact of evidence-based medications on cardiovascular and cerebrovascular outcomes in patients with acute coronary syndrome post-revascularization in oman
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204429/
https://www.ncbi.nlm.nih.gov/pubmed/37218961
http://dx.doi.org/10.3390/pharmacy11030079
work_keys_str_mv AT alhadithydaliaahmed theprevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT almaqbalijuhainasalim theprevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT alriyamiadil theprevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT alzaabimohammed theprevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT alzakwaniibrahim theprevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT alhadithydaliaahmed prevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT almaqbalijuhainasalim prevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT alriyamiadil prevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT alzaabimohammed prevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman
AT alzakwaniibrahim prevalenceandimpactofevidencebasedmedicationsoncardiovascularandcerebrovascularoutcomesinpatientswithacutecoronarysyndromepostrevascularizationinoman